Clinical Trial Update: Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating ferumoxytol-enhanced MRI to monitor pembrolizumab response in glioblastoma; the study was terminated and results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• FERUMOXYTOL (ferumoxytol)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2025-09-09